Literature DB >> 6870656

[Malignant tumors of the salivary glands: early diagnosis, follow-up and therapy].

R Chilla, R Casjens, U Eysholdt, M Droese.   

Abstract

Problems of early recognition, postoperative care, and therapy were studied in 207 patients with malignant tumors of the salivary glands, who were treated from 1965 to 1975. Early recognition of these malignant tumors is hampered by the circumstance that only a very short time span is available for diagnosis of the highly malignant types and by the lack of knowledge about specific risk groups among the population. Important for postoperative care is the high rate of local tumor recurrence, especially of salivary-duct, mucoepidermoid, acinic-cell, and adenoid-cystic carcinomas, ranging from 71% to 83%. Late recurrence is frequent. There is also a close connection between local recurrence and lymphogenic or hematogenic formation of metastases. The therapy of choice for malignant tumors of the salivary glands is surgery and, depending on the tumor type, postoperative irradiation. Chemotherapy is at present still of minor importance. Histologic tumor type and tumor stage determine the extent of the surgical procedures, which range from lateral parotidectomy with preservation of the facial nerve to radical parotidectomy with or without reconstruction of the facial nerve. In spite of radical surgery, many malignomas of the salivary glands, particularly the adenoid-cystic carcinomas, tend to recur. In such cases the long-term prognosis is poor and cannot be improved by postoperative irradiation. Supplemented by the experience gained in postoperative care, we have summarized the guidelines along which these 207 salivary-gland malignomas were treated into a modified concept of therapy.

Entities:  

Mesh:

Year:  1983        PMID: 6870656     DOI: 10.1007/bf00453728

Source DB:  PubMed          Journal:  Arch Otorhinolaryngol        ISSN: 0302-9530


  14 in total

1.  Therapy of parotid tumors.

Authors:  J Haubrich; A Miehlke
Journal:  Chirurg       Date:  1978-02       Impact factor: 0.955

2.  Radiation therapy in the treatment of malignant salivary gland tumors.

Authors:  D Elkon; M Colman; F R Hendrickson
Journal:  Cancer       Date:  1978-02       Impact factor: 6.860

3.  Salivary gland tumours.

Authors:  C Butler
Journal:  J Laryngol Otol       Date:  1972-08       Impact factor: 1.469

4.  Variations in radiosensitivity of various types of malignant salivary-gland tumour.

Authors:  P A Jakobsson; C M Eneroth
Journal:  Acta Otolaryngol Suppl       Date:  1969

5.  Complete response of a metastatic adenoid cystic carcinoma of the parotid gland to chemotherapy.

Authors:  J L Skibba; J D Hurley; H V Ravelo
Journal:  Cancer       Date:  1981-06-01       Impact factor: 6.860

6.  Adenoid cystic carcinoma of the head and neck. Controllable and uncontrollable factors in treatment and prognosis.

Authors:  R Chilla; R Schroth; U Eysholdt; M Droese
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  1980       Impact factor: 1.538

7.  Chemotherapy of malignant major salivary gland neoplasms: a 25-year review of M. D. Anderson Hospital experience.

Authors:  R Rentschler; M A Burgess; R Byers
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

8.  [Intraarterial therapy of maxillary adenoid cystic carcinoma using cis-platinum (author's transl)].

Authors:  J von Scheel; E R Kastenbauer
Journal:  HNO       Date:  1981-09       Impact factor: 1.284

9.  Chemotherapy for salivary gland cancer.

Authors:  J Y Suen; M E Johns
Journal:  Laryngoscope       Date:  1982-03       Impact factor: 3.325

10.  [The influence of therapy on adenoid cystic carcinomas of the parotid gland (author's transl)].

Authors:  R Chilla; R Schrot; U Eysholdt; M Droese
Journal:  HNO       Date:  1981-04       Impact factor: 1.284

View more
  1 in total

1.  [Unilateral cheek tumor. Case report and differential diagnoses].

Authors:  S Neugebauer; E-I Grussendorf-Conen; J Frank; F Abuzahra
Journal:  Hautarzt       Date:  2004-01       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.